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Abstract
Background: Opioid prescribing for a range of health issues is increasing globally. The risk of fatal and non-fatal
overdose is increased among people prescribed strong opioids: in high doses in the context of polypharmacy (the
use of multiple medications at the same time), especially with other sedatives; and among people with multiple
morbidities including cardiorespiratory, hepatic and renal conditions. This study described and quantified the
prescribing of strong opioids, comorbidities and other overdose risk factors among those prescribed strong opioids,
and factors associated with high/very high opioid dosage in a regional health authority in Scotland as part of a
wider service improvement exercise.
Methods: Participating practices ran searches to identify patients prescribed strong opioids and their characteristics,
polypharmacy, and other overdose risk factors. Data were anonymised before being analysed at practice and
patient-level. Morphine Equivalent Doses were calculated for patients based on drug/dose information and classed
as Low/Medium/High/Very High. Descriptive statistics were generated on the strong opioid patient population and
overdose risk factors. The relationship between the prescribing of strong opioids and practice/patient-level factors
was investigated using linear and logistic regression models.
Results: Eighty-five percent (46/54) of GP practices participated. 12.4% (42,382/341,240) of individuals in
participating practices were prescribed opioids and, of these, one third (14,079/42,382) were prescribed strong
opioids. The most common comorbidities and overdose risk factors among strong opioid recipients were pain
(67.2%), cardiovascular disease (43.2%), and mental health problems (39.3%). There was a positive significant
relationship between level of social deprivation among practice caseload and level of strong opioid prescribing
(p < 0.001). People prescribed strong opioids tended to be older (mean 59.7 years) and female (8638, 61.4%) and,
among a subset of patients, age, gender and opioid drug class were significantly associated with prescribing of
High/Very High doses.
Conclusions: Our findings have identified a large population at potential risk of prescription opioid overdose. There
is a need to explore pragmatic models of tailored interventions which may reduce the risk of overdose within this
group and clinical practice may need to be tightened to minimise overdose risk for individuals prescribed high
dose opioids.
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Background
Scotland has one of the highest rates of opioid-related
overdose mortality in Europe, with the rates of fatal
overdose continuing to increase [1]. These overdoses
mainly occur among users of illicit opioids such as her-
oin, or opioids prescribed for dependence such as
methadone and buprenorphine [1]. However, individuals
who are prescribed opioids for clinical reasons can also
have increased Prescription Opioid Overdose Risk
(POOR) [2, 3]. While deaths involving prescription opi-
oids are not routinely reported as a discrete group in
Scotland, of the 1264 drug-related deaths in Scotland in
2019, opiates/opioids were implicated in 1092 (86%) in-
cluding prescribable opioids such as methadone, bupre-
norphine, and codeine/dihydrocodeine, reflecting a trend
observed in recent years [1].
Individuals are prescribed opioids for acute pain,
cancer pain and chronic non cancer pain (CNCP); for
the management for dependence on illicit opioids;
and for palliative care [4]. Opioids can effectively
manage acute and cancer pain but there is limited
evidence of their efficacy in CNCP [5], with studies
finding variable quality evidence of short to medium-
term analgesic benefits. Studies have highlighted an
increased risk of harm directly related to opioid pre-
scribing [6–8]. In the last 20 years, there have been
considerable increases in the prescription of opioids
for CNCP, predominantly in high-income countries
including the USA, Canada and Australia. This in-
crease is perceived to be caused by several interre-
lated systematic, political, economic, prescribing and
governance developments and issues that syndemically
created a large population of people prescribed opi-
oids, with questionable benefits [9–11]. Furthermore,
this may have contributed to increasing or persistent
expectations by patients for the unqualified continu-
ation of these prescriptions [12, 13]. It also reflects
the cultural and social standpoints and practices of
clinical, legal and regulatory communities which fluc-
tuate over time, as documented in the narrative re-
view by Rosenblum and colleagues [14]. Some
countries, including the USA and Canada, have
responded to these concerns through increased moni-
toring or regulation of these prescriptions, although
these measures have been associated with some un-
welcome, unintended consequences such as increased
use of illicit opioids [15, 16, 17].
In Scotland the number of individuals prescribed opi-
oids for CNCP increased by 66% between 2006 and 2016
[18]. However, within this broader trend, opioid pre-
scribing is not evenly distributed across society; areas ex-
periencing higher levels of socio-economic deprivation
tend to experience higher rates of opioid prescribing, as
evidenced in England [19, 20, 21] and Scotland,
particularly in relation to the prescribing of strong opi-
oids [22, 23].
While some literature may discuss two distinct groups
of opioid users, clinically, the illicit opioid using and the
CNCP populations share similarities [24]. A recent Scot-
tish study of people over 35 years old with a drug prob-
lem found that 52% self-reported CNCP [25]. The
CNCP population may overuse prescribed analgesia, be
prescribed methadone, or buy illicit heroin and/or
methadone; others become iatrogenically dependent due
to using in excess of prescribed doses [26]. Australian
studies have identified that those who were prescribed
strong opioids or opioids on a longer-term basis for
CNCP were those who experienced a range of physical
and mental health challenges, as well as social disadvan-
tage [26, 27]. Similarly, those who are prescribed opioids
for pain related pathologies, palliative care, or illicit opi-
oid dependency, often experience comorbidities contrib-
uting to POOR. Many cancer patients live with multiple
comorbidities [28]. Those using illicit opioids often have
co-occurring problems with substances including drugs
and alcohol, as well as mental health problems [11, 29]
and overdose risk is increased when these are present
[11, 30, 31].
Additionally, polydrug use and polypharmacy practices
are confounding factors that also merit consideration
with national and international guidelines [32, 33] advis-
ing against the co-prescribing of these in combination
with other sedatives, such as hypnotics and other anxio-
lytics (e.g. benzodiazepines), and gabapentinoids (gaba-
pentin and pregabalin). Irrespective of the reasons for
opioid prescribing, the risk of fatal and non-fatal over-
dose from co-occurring conditions may be increased in
individuals where comorbidities compromise cardiore-
spiratory, renal and/or hepatic function [11].
Higher doses of opioids are also associated with in-
creased overdose risk. The UK Faculty of Pain Medicine
describes how the risk of harm increases substantially at
doses of > 120 mg morphine equivalent dose (MED),
with no additional clinical benefits at these doses [32].
Similarly, the United States’ Centers for Disease Control
and Prevention (CDC) Guidelines for Prescribing Opioids
for Chronic Pain notes “clinicians should use caution
when prescribing opioids at any dosage, [and] should
carefully reassess evidence of individual benefits and
risks when increasing dosage to ≥50 morphine milligram
equivalents (MME)/day, and should avoid increasing
dose to ≥90 MME/day” [33].
In 2018, the Scottish Government and NHS Scotland
published the Quality Prescribing in Chronic Pain – a
guide for improvement guidance to encourage a quality
improvement approach to the review of prescribing of
key analgesic medicines in Primary Care including opi-
oids and gabapentinoids [18]. These guidelines
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recommend that clinicians review patients co-prescribed
analgesics and other potentially problematic drugs in-
cluding gabapentinoids, and initiate conversations with
patients about expectations surrounding what pharma-
cological treatment, including increases in doses, can
realistically be offered in light of the evidence [18].
Rationale
To develop appropriate, tailored responses to reduce
POOR, it is essential to understand the population at
risk. This includes the number of individuals prescribed
opioids, their demographic characteristics and their clin-
ical profiles, including comorbidities, polypharmacy and
prescribed doses. Previous analysis of dispensed medica-
tions in Scotland identified factors associated with
strong opioid prescribing stratified by sociodemographic
variables [22]. This study develops the understanding of
risk relating to comorbidities and concomitant
prescribing.
The aims of the study were two-fold. Firstly, building
on previous quality improvement work undertaken in
the NHS Fife regional health authority (‘Health Board’)
area of Scotland [18], to quantify and analyse the nature
of current prescribing of strong opioids in community
(‘primary’) healthcare by providing absolute numbers of
patients in participating General Practice (GP) practices.
Secondly, to identify cohorts of individuals who may be
at risk of prescription opioid overdose, due to dosing
schedules being higher than recommended; physical
and/or mental health comorbidities; known adverse drug
interactions and/or any combination of these factors.
This quality improvement exercise formed part of a
wider study which also explored the acceptability of a
bespoke take-home naloxone package for individuals
prescribed opioids for CNCP via qualitative interviews.
Methods
This study used data extracted from the National Health
Service (NHS) primary care information systems to iden-
tify and describe a cohort of patients potentially in the
POOR category. Data searches were undertaken both at
practice and patient-level.
Setting and scope
NHS Fife is an administrative and geographical Health
Board serving a population of approximately 370,000
with 54 general practices grouped into 7 locality-based
clusters. Potentially eligible patients were those regis-
tered at participating GP practices on 31/10/19 who
were identified using the Prescribing Information System
for Scotland which holds collated data on all prescrip-
tions written in the country [34]. Patients were eligible
for inclusion if they had been prescribed one or more
strong opioids, alone or in combination with
benzodiazepines, z-drugs, and/or gabapentinoids in the
six months preceding this study. Based on the team’s
clinical expertise and the British National Formulary
(BNF) categorisation [35], strong opioids were defined as
medications containing buprenorphine in either tablet
or patch formulation, diamorphine, fentanyl, hydromor-
phone, methadone, morphine, oxycodone, pentazocine,
pethidine, tapentadol, or tramadol.
Procedures and data extraction
No formal ethical and/or research governance approvals
were required as this study was undertaken as part of a
quality improvement process. Primary Care Clinical Di-
rectors and Cluster Quality Leads gave approval for co-
author DS to invite all NHS Fife practices to participate.
Data collection was led by the Fife Pain Management
Service Lead Pharmacist (DS). Coding was developed
and emailed to participating pharmacy teams, enabling
them to extract relevant prescribing data from their clin-
ical information system via EMIS Web, a UK-wide clin-
ical IT system that stores and enables the sharing of
information about patients and practices across health-
care settings [36].
A search strategy was devised for consistency across
the practices [see Additional File 1] and searches were
run by practice pharmacy teams between October and
December 2019. Two searches were conducted. The first
captured practice-level data on prescribing of strong opi-
oids and occurrence of co-morbidities. POOR risk fac-
tors (polypharmacy and co-morbidities) were identified
by searching on Read codes (version 2), a clinical coding
system used in primary care in Scotland since the 1980s
that can be mapped to ICD10 [37]. The second search
captured patient characteristics (age, gender) and infor-
mation from strong opioid prescriptions (drug, dose,
date). All patients prescribed strong opioids were in-
cluded as it was not possible to differentiate between
prescribing for cancer pain and CNCP in the timescale
available to conduct the project. Searches were devised
to exclude multiple counting of a drug for the same pa-
tient. This ensured that, for example, monthly prescrip-
tions for a specific drug were counted only once within
the study period. Therefore, the data relate to the num-
ber of differing drug items, and not the total number of
prescription items issued per patient prescribed during
the study period, which would be considerably higher.
Returns were pseudonymised by replacing practice
names with a numeric identifier. Practice returns were
collated in an encrypted, password-protected Microsoft
Excel document only accessible to members of the study
team involved in data analysis. Each practice returned
two files: firstly, practice-level data on the numbers of
patients who received opioid prescriptions, concomitant
prescribed high-risk medicines, or relevant
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comorbidities. Secondly, patient-level data including age,
gender and details of prescribed strong opioid items in-
cluding drug name, dose and date of issue. All partici-
pating practices consented for their pseudonymised data
to be reported in aggregated cluster and health board
levels. All but one practice consented for pseudonymised
practice-level data to be reported; this practice’s data
were included in aggregated summary statistics but ex-
cluded from practice-level reports. NHS Information
Services Division Scotland provided data on practice
population by deprivation quintiles as at the end of June
2019, using the Scottish Index of Multiple Deprivation
(SIMD) definitions which quantifies local deprivation
based on seven domains: income, employment, educa-
tion, health, access to services, crime and housing [38].
Analysis
Descriptive statistics and statistical models were applied
using R version 4.0.0 [39] and the significance level for
tests and models was set at 5%. For practice-level data,
tables and summary statistics were generated to describe
the number and proportion of practices participating
and patients included overall and by cluster. The pro-
portion of patients at participating practices prescribed
strong opioids was summarised, as were the proportions
prescribed any opioid and concurrent prescribing of
strong opioids plus other central nervous system depres-
sant drugs for comparison. Data on ‘Opioids excluding
Tramadol’ was provided as there is a lack of clinical con-
sensus whether to consider Tramadol as a weak or
strong opioid. Overdose risk factors including polyphar-
macy and comorbidities were described. An unadjusted
linear regression was developed to describe the relation-
ship between the proportion of a practice’s caseload resi-
dent in SIMD 1 areas and the proportion of patients
prescribed a strong opioid.
Patient-level data were recoded to calculate the max-
imum daily MEDs prescribed for each patient using con-
version factors informed by the literature [40, 41] and
available as an additional file [Additional file 2]. Opioid
conversion factors are an approximate guide only be-
cause comprehensive data are lacking and there is sig-
nificant inter-individual variation. The total MEDs were
then categorised as low, medium, high or very high in
line with guidance from the CDC and the Faculty of
Pain Medicine [32, 33] (Table 1). MEDs were not
calculated for patients prescribed buprenorphine tablets
as this preparation does not have a calculable MED
under current guidelines due to complex, non-linear
pharmacokinetics. Prescriptions were classed as concur-
rent if they had matching date of issue.
Descriptive statistics present the distribution of age,
gender, drugs prescribed, and items per patient. MEDs
were summarised for patients on a methadone-
containing regimen versus those not prescribed metha-
done as this drug had the highest median MEDs among
our cohort due to the high morphine equivalence con-
version factor. The proportion of patients where MEDs
could not be calculated, and the reasons for this, were
described.
Patient characteristics associated with prescribing of
L/M MEDs versus H/VH were tested using an inde-
pendent samples t-test to assess the relationship with
age, and a chi squared test for the relationship with gen-
der. Differences in the proportion of patients prescribed
VH meds and the proportion with missing MEDs were
compared for patients prescribed methadone versus
those on methadone-free regimens using two-sample
tests for equality of proportions.
The association between prescribed MEDs and po-
tential risk factors (age, gender and opioid class) was
investigated using logistic regression. A subset of
4003 patients was selected for this model, including
those with data to support calculation of maximum
MEDs (the dependent variable); who were prescribed
one opioid only (to allow comparison across drug
classes); who were prescribed a ‘high-volume opioid’
prescribed to more than 50 individuals in the sample;
and where at least 10 patients were prescribed a H/
VH dose: methadone (n = 272), fentanyl (242), mor-
phine (2136), oxycodone (1353). Associations between
predictive factors and the outcome were expressed as




Forty-six of the 54 invited GP practices in NHS Fife
participated, a response rate of 85%. Of the eight
non-participating practices, three declined and five
were willing to participate but could either not run
the search (n = 4) or were unable to provide all the
required data (n = 1). The proportion of practices par-
ticipating in each cluster ranged from 40% to 100%,
with all but one achieving over 80% (Table 2). With a
combined practice list size of 341,240, participating
practices represented 88.4% of registered GP patients
in NHS Fife. The median (Inter-Quartile Range, IQR)
list size per practice was 7365 (3704) patients.
Table 1 Morphine Equivalent Dose (MED) category calculations




> 120 Very High (VH)
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Practice-level data
Opioid prescribing
In the previous six months 42,382 (12.4%) of individuals
were prescribed any opioid. Within these, 14,079 were
prescribed a strong opioid, representing 4.1% of the
overall caseload and 33.2% of patients who had been
prescribed any opioid [see Supplementary Table 1, Add-
itional File 3]. At practice-level, the median (IQR) num-
ber and proportion of patients prescribed a strong
opioid were 262.5 (176.8) and 4.2% (2.4%) respectively
(Fig. 1) [see Supplementary Table 2, Additional File 3].
Comorbidities and overdose risk factors
Among the 14,079 patients who had been prescribed
strong opioids, the most commonly reported comorbidi-
ties and overdose risk factors included pain (67.2%), car-
diovascular disease (43.2%), mental health problems
(39.3%) and respiratory disease (25.6%) [see Supplemen-
tary Table 3, Additional File 3], with evidence of
variation in the distribution of these factors at practice-
level (Fig. 2).
The proportion of the practice caseload resident in the
most deprived (‘SIMD1’) areas was significantly associ-
ated with the proportion prescribed a strong opioid (p <
0.001) (Table 3). Model diagnostics indicated that one
outlying practice, where 91% of the caseload lived in
SIMD1 areas, exerted unusually high leverage in the
model. The model remained significant (p < 0.001) when
repeated with this practice excluded.
Patient-level data
Practices provided data on 15,304 opioid items pre-
scribed to 14,078 patients. Patient age ranged from 4
to 103 years with a mean (Standard Deviation, SD) of
59.7 (16.4) years. Most patients were female (8638,
61.4%), and the vast majority were prescribed one
opioid (12,944, 91.9%). Eleven patients were aged less
than 16 years with a median (IQR) age of 11 (7.5)
years and a median (IQR) MED of 30 (41.8). The
most commonly prescribed opioids were tramadol
(9179 /15,304 items), morphine (3066/15,304), and
oxycodone (1900/15,304). The range of MEDs per
prescribed item was 0.4–1920 with a median (IQR) of
60 (30), and these values varied by drug class (Fig. 3)
[see Supplementary Table 4, Additional File 3].
There was a small but statistically significant difference
in the age of patients prescribed L/M MEDs (mean 59.9,
SD 16.4 years) versus H/VH MEDs (57.9, 17.0 years)
(t (13,484) = 3.983, p < 0.001). There was also a statisti-
cally significant difference in the proportion of females
who were prescribed H/VH MEDs (577, 6.9%) compared
to males (522, 10.1%) (χ2 (1, N = 13,486) = 42.464,
p < 0.001). Patients prescribed methadone-containing
Table 2 Practice participation and list size by cluster






1 1 5 83% 34,676
2 0 10 100% 65,247
3 0 8 100% 41,006
4 1 6 86% 46,832
5 1 6 86% 59,693
6 2 9 82% 69,211
7 3 2 40% 24,575
NHS Fife 8 46 85% 341,240
Fig. 1 Opioid prescribing in the previous six months (per practice). BZD = benzodiazepines; Gaba = gabapentinoids
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regimens were significantly more likely to have VH
MEDs (265/387 vs. 433/13,692, p < 0.001), and to have
missing MED information (95/387 vs. 497/13,692,
p < 0.001) when compared to those not prescribed
methadone (Fig. 4). [See Supplementary Tables 5 and 6,
Additional File 3].
Multivariate analysis was conducted on a subset of
4003 patients, of whom 785 (19.61%) were prescribed H/
VH MEDs. Age, gender, and drug class were all signifi-
cantly associated with the likelihood of being prescribed
H/VH MEDs (Table 4). After adjustment, male sex was
associated with increased odds of H/VH MEDs (aOR
1.48, 95% CI 1.23–1.78, p < 0.001). Each additional year
of a patient’s age was associated with a 1% reduction in
the odds of receiving H/VH MEDs. Compared to metha-
done patients, those prescribed fentanyl (aOR 0.10, 95%
CI 0.06–0.16), morphine (aOR 0.02, 95% CI 0.01–0.03)
and oxycodone (aOR 0.03, 95% CI 0.02–0.05), had sig-
nificantly reduced odds of being of being prescribed H/
VH MEDs.
Missing MEDs
It was not possible to calculate MEDs for 593 (3.87%)
prescribed items, including 496 items where prescrip-
tions did not include maximum daily dose information
[see Supplementary Table 6, Additional File 3], and for
97 oral buprenorphine items due to the complex non-
linear pharmacokinetics of this preparation. Maximum
daily dose information was omitted from 23.8% (92/386)
of all methadone items, 21.0% (4/19) of all pethidine
items, and 33.3% (2/6) of all diamorphine items
prescribed.
Discussion
This study identified and quantified the size and nature
of the population prescribed strong opioids in one NHS
Health Board area in Scotland. 12.4% of individuals were
prescribed opioids and, of these, one third were pre-
scribed strong opioids. The population can be charac-
terised as generally older patients with POOR
comorbidities who were prescribed more than one anal-
gesic medication. This group experienced a range of co-
morbidities with pain, cardiovascular/circulatory disease,
and mental health issues being the most common.
Of particular concern regarding overdose risk are car-
diovascular disease and respiratory disease [11] which
were present in 43.2% and 25.6% patients respectively.
Both compromise physiological resilience and further in-
crease risk of overdose [11]. Mental health problems
were frequently reported and are commonly associated
with prescription opioid use, as well as the use of alcohol
and other drugs [26, 27]. This study did not explore the
number of comorbidities per patient; such analysis
would be desirable in further research and enable more
effective targeting of interventions. At practice-level,
Fig. 2 Recorded comorbidities and overdose risk factors among strong opioid recipients (practice-level). Excl. hypert. = excluding hypertension
Table 3 Regression of proportion of caseload resident in SIMD
















Adj. R2 0.453 0.465
Model p < 0.001 p < 0.001
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there was a positive relationship between levels of strong
opioid prescribing and deprivation, in line with the refer-
enced literature [19, 20, 21, 23]. Prescriptions lacking
stated maximum daily dose information, for example
those prescribed as ‘when required’, could further lead
to inadvertent overdose by the patient or carer. Al-
though methadone items were a small proportion of
strong opioids prescribed among this cohort, patients on
methadone-containing regimens were disproportionately
exposed to very high MEDs, and methadone prescrip-
tions were more likely to lack information on maximum
daily dosing.
Strengths and limitations of the study
There was a high level of participation (85%) in this
study from GP practices. The reported data covers a
high percentage of the NHS Fife population and should
be broadly representative of prescribing activity and pa-
tient characteristics across the Health Board area. This
study builds on previous analyses of opioid prescribing
by volume and demographic characteristics, with the im-
portant addition of data on comorbidities and concomi-
tant prescribing of high-risk medicines that could
inform policy and practice developments across Scotland
and beyond.
Fig. 3 Prescribed MEDs by drug class (excluding buprenorphine tablets). BUPP = buprenorphine patches; DIA = diamorphine; FEN = fentanyl;
HYD = hydrocodone; METH =methadone; MOR =morphine; OXY = oxycodone; PEN = pentazocine; PETH = pethidine;
TAP = tapentadol; TRAM = tramadol
Fig. 4 Maximum MEDs per patient by methadone prescribing status
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This study has several limitations. The level of Read
coding across the participating GP practices was variable
and so the number of patients with comorbidities that
increase overdose risk may be underestimated. Comor-
bidity searches were conducted at population, rather
than patient-level. This was compatible with the aims
and parameters of this study. Data extraction relied on
the goodwill of practice staff and pharmacy technicians
and there was an associated trade-off between coverage
and depth of data collection. As the analysis was under-
taken on prescriptions generated at practice-level, and
not those presented for dispensing via community phar-
macy, the information must be regarded as a proxy
measure of ‘intention to treat’ dosing data, rather than
doses actually dispensed and/or consumed by patients.
Prescriptions were classed as concurrent if they had the
same start date and this conservative definition excluded
other potentially overlapping prescriptions due to limita-
tions in the data provided.
Given the decision to be inclusive of the entire POOR
population, methadone and buprenorphine prescriptions
were included, but these are less easily compared using
MEDs. Methadone to morphine conversions are very
different from other drug conversions and are dose-
dependent, increasing exponentially as dose increases
[41]. We opted to report methadone separately when
calculating MED so as not to skew data. The criteria
used to select patients for the analysis of prescribed
MEDs and POOR risk factors resulted in just 4003 or
28.4% of the cohort being included in this analysis. Fi-
nally, the limitations of the searches meant it was not
possible to differentiate prescribing for cancer pain,
CNCP and other conditions.
In terms of clinical relevance, this study has quantified
the potential size of the POOR population at health
board, cluster and GP practice-levels, building on previ-
ous work in this area [18, 23]. Evidence of higher rates
of strong opioid prescribing in areas of deprivation and
the prevalence of comorbidities can help inform public
health, prescribing, chronic disease management and
other strategies to address possible overdose risk and re-
duce health inequalities. This study provides information
and analysis in greater detail at practice level. It high-
lights issues around prescribed dosing through the ab-
sence of maximum recommended daily number of doses
where prescriptions include ‘when required’ dosing in-
formation, or the absence of a prescribed dose
altogether. In both cases this may increase risk of unin-
tended overdose. It highlights the difficulty in assessing
risk based on MED in some groups of patients e.g., those
receiving buprenorphine tablets in opioid substitution
therapy. It identifies groups of patients at potentially
higher risk of opioid overdose events due to high dose
opioid prescribing; use of concomitant prescribed medi-
cation which increase respiratory depression; and pre-
scribing in patients with comorbidities that can increase
opioid toxicity risk or are associated with higher risk of
accidental or non-accidental overdose.
Implications for policy and practice
Our results have several implications for opioid prescrib-
ing policy and practice to improve patient safety. Clini-
cians should routinely consider comorbidities that are
associated with increased risk of overdose, polyphar-
macy, and total opioid MEDs when prescribing opioids.
Prescribers should ensure there is no escalation of com-
bined opioid doses above 90 mg MED in CNCP, in line
with Scottish Intercollegiate Guidelines Network
(‘SIGN’) 136 or equivalent international guidance [43].
Specific attention should be paid to MEDs and risk fac-
tors among patients receiving methadone-containing
regimens.
Prescribers and dispensers (pharmacists) should pro-
vide patients with clear information on health condi-
tions, behaviours and drug combinations that could
place them at higher risk of overdose when taking opi-
oids. Patients receiving opioids should also be offered
regular review that includes assessment of the conditions






Unadjusted model Adjusted model
ORs CI P aORs CI p
(Intercept) 0.24 0.23–0.26 < 0.001 15.72 9.47–26.09 < 0.001
Age 0.97 0.96–0.97 < 0.001 0.98 0.98–0.99 < 0.001
Female (ref) 2485 378 (15.21)
Male 1518 407 (26.81) 2.04 1.74–2.39 < 0.001 1.48 1.23–1.78 < 0.001
Methadone (ref) 272 248 (91.18)
Fentanyl 242 86 (35.54) 0.05 0.03–0.09 < 0.001 0.10 0.06–0.16 < 0.001
Morphine 2136 238 (11.14) 0.01 0.01–0.02 < 0.001 0.02 0.01–0.03 < 0.001
Oxycodone 1353 213 (15.74) 0.02 0.01–0.03 < 0.001 0.03 0.02–0.05 < 0.001
ORs = Odds Ratios. aORs = Adjusted Odds Ratios; ref. = reference category; N = total number
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for which opioids were indicated, concomitant risk fac-
tors, response to treatment, and discussion of alternative
pain management and prescribing strategies. These rec-
ommendations depend on prescribers and dispensers be-
ing skilled and supported to deliver harm reduction
conversations and interventions. In the context of large
numbers of patients and limited clinical resources, a tar-
geted approach could be considered which initially
prioritises review of prescribed > 90mg MEDs, and those
with polypharmacy that includes opioids, gabapentinoids
and hypnotics/anxiolytics. These recommendations cor-
respond with recent findings from Campbell et al.’s [44]
study which focused opioid-related harms for the CNCP
population and encouraged a holistic assessment of the
needs, risks and benefits for each individual, when ad-
dressing concerns of patient safety.increased use of illicit
opioids
These findings demonstrate that additional clinical
governance is required to reduce risk within this group.
Greater leadership is needed on safer prescribing at na-
tional, regional, and local levels, with the importance of
understanding prescribing in the context of an individual
patient being a key part of this discussion. We recom-
mend that other health authorities undertake similar au-
dits and service improvement exercises, as well as
interventions which may reduce the risk of overdose
within this group. As outlined, there are a number of
practical ways to reduce risk of inadvertent overdose,
which also include the specification of maximum daily
dosing in opioid prescriptions, minimising polyphar-
macy, especially with other CNS depressants, co-
prescribing of naloxone, gradually tapering doses, and
monitoring and responding to warning signs such as re-
quests for early refills [45]. These need to be addressed
or facilitated by prescribers or community pharmacists
within a clear governance structure.
Finally, we acknowledge the potential for adverse con-
sequences resulting from rapid reduction or withdrawal
of prescriptions for people taking opioids that have been
observed elsewhere, including the USA and Canada,
such as a shift towards use of illicit opioids [15, 16, 17].
We also recognise that each country is unique and may
have specific drivers for opioid prescribing which require
tailored and patient-focussed responses. However, the
findings from our study support others which highlight
the risks of harm posed by prescribed opioids, and the
need for decisive responses.
Conclusions
This study described and quantified the population of
primary care patients with POOR in one Scottish Health
Board and described the characteristics of patients and
their prescriptions that increase this risk. The study
found a large cohort of patients prescribed strong
opioids with increased POOR due to high doses, comor-
bidities, and polypharmacy. Other areas should under-
take practice quality improvement exercises such as this,
and develop staff training and patient-centred interven-
tions, which may reduce the risk of overdose among this
group.
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